abstract details

The summaries are free for public use. ARTHROS will continue to add and archive summaries of articles deemed relevant to ARTHROS by our Faculty.

Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis

Author

Strand V1, Elaine Husni M2, Betts KA3, Song Y4, Singh R5, Griffith J5, Beppu M5, Zhao J4, Ganguli A5. BMC Rheumatol. 2018 Feb 12;2:3. doi: 10.1186/s41927-018-0011-1. eCollection 2018.

Author Information

1 Stanford University, Palo Alto, CA USA.

2 Cleveland Clinic, Cleveland, OH USA.

3 Analysis Group Inc., 333 South Hope Street, 27th Floor, Los Angeles, CA 90071 USA.

4 Analysis Group Inc., Boston, MA USA.

5 AbbVie Inc., Mettawa, IL USA.

Abstract

BACKGROUND: 

Multiple targeted immunomodulators (TIMs) for psoriatic arthritis (PsA) treatment are available, but limited studies have directly compared these agents. This study indirectly compared the efficacy of TNF-α, interleukins, and phosphodiesterase-4 inhibitors for treatment of active PsA.

METHODS: 

A systematic literature review was conducted to identify phase III randomized controlled trials (RCTs) for adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, ustekinumab, secukinumab, and apremilast in active PsA. Joint (ACR20/50/70) and skin outcomes (PASI75/90) at Week 24 with each TIM were estimated via a Bayesian network meta-analysis, and the incremental cost per responder over the first 24 weeks of treatment was calculated. Similar analyses were conducted in a subgroup of biologic-naïve patients.

RESULTS: 

Seventeen RCTs were identified; 13 included ACR and/or PASI responses at Week 24. Among the overall population, patients receiving adalimumab, golimumab, and infliximab showed higher ACR20/50/70 (adalimumab: 61.2/42.8/40.8%, golimumab: 61.6/39.8/27.4%, infliximab: 56.2/57.1/34.2%) and PASI75/90 (72.7/55.5%, 74.1/57.2%, and 77.1/61.0%, respectively) responses at Week 24 compared with other TIMs. In terms of cost-effectiveness, these treatments were also associated with the lowest incremental cost per responder for both skin and joint outcomes. Similar rankings of efficacy and incremental cost per responder were observed in the analysis among biologic-naive patients.

CONCLUSIONS: 

Adalimumab, golimumab, and infliximab were associated with higher efficacy and lower incremental costs per responder for both joint and skin responses in active PsA.